Gladius Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Gladius Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,390	Closed	-$36.5K	–	79
2024 Q3	$36.5K	Buy	+4,390	New	+$34.3K	﹤0.01%	169
2024 Q2	–	Sell	-6,480	Closed	-$39.3K	–	305
2024 Q1	$39.3K	Sell	6,480 -1,513	-19%	-$8.53K	0.01%	217
2023 Q4	$48.5K	Sell	7,993 -1,233	-13%	-$5.49K	0.01%	175
2023 Q3	$38.9K	Buy	+9,226	New	+$34.4K	﹤0.01%	230
2022 Q4	–	Sell	-16,596	Closed	-$34K	–	353
2022 Q3	$34K	Buy	+16,596	New	+$46.5K	﹤0.01%	265

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Gladius Capital Management's AMRX Position: Q4 2024 in Review

Gladius Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q4 2024, closing a stake of 4,390 shares — an estimated $36.5K sold.

Gladius Capital Management first reported a position in AMRX in Q3 2022 and held it in 5 quarters. The position peaked at $48.5K in Q4 2023. 199 funds tracked by Wall St. Rank hold AMRX as of Q4 2024.

Gladius Capital Management reported no remaining Amneal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Gladius Capital Management sold 4,390 Amneal Pharmaceuticals shares in Q4 2024, an estimated $36.5K.
Gladius Capital Management first reported a position in Amneal Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Gladius Capital Management's Amneal Pharmaceuticals position peaked at $48.5K in Q4 2023.
199 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.